Oncolytics Biotech (TSE:ONC) Stock Passes Above Two Hundred Day Moving Average – Here’s Why

Oncolytics Biotech Inc. (TSE:ONC) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of C$14.90 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares trading hands.

Oncolytics Biotech Price Performance

The company has a fifty day simple moving average of C$14.90 and a two-hundred day simple moving average of C$14.90. The company has a debt-to-equity ratio of 14.58, a quick ratio of 8.86 and a current ratio of 2.88. The company has a market capitalization of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.